Timapiprant sodium
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 330217

CAS#: 950688-14-9 (sodium)

Description: Timapiprant, also known as OC000459, is a potent, selective and orally active CRTH2 antagonist. OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. OC000459 inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils. OC000459 treatment inhibited LAR and post-allergen increase in sputum eosinophils. OC000459 appears to inhibit allergic inflammation in asthma.


Price and Availability

Size
Price

50mg
USD 450
500mg
USD 1950
Size
Price

100mg
USD 750
1g
USD 2950
Size
Price

200mg
USD 1250
2g
USD 5450

Timapiprant sodium, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 330217
Name: Timapiprant sodium
CAS#: 950688-14-9 (sodium)
Chemical Formula: C21H16FN2NaO2
Exact Mass:
Molecular Weight: 370.3592
Elemental Analysis: C, 68.10; H, 4.35; F, 5.13; N, 7.56; Na, 6.21; O, 8.64


Related CAS #: 851723-84-7 (free acid)   950688-14-9 (sodium)  

Synonym: OC000459; OC-000459; OC 000459; Timapiprant; Timapiprant sodium;

IUPAC/Chemical Name: sodium 2-(5-fluoro-2-methyl-3-(quinolin-2-ylmethyl)-1H-indol-1-yl)acetate

InChi Key: XKRNYIKRDAGPQZ-UHFFFAOYSA-M

InChi Code: InChI=1S/C21H17FN2O2.Na/c1-13-17(11-16-8-6-14-4-2-3-5-19(14)23-16)18-10-15(22)7-9-20(18)24(13)12-21(25)26;/h2-10H,11-12H2,1H3,(H,25,26);/q;+1/p-1

SMILES Code: O=C([O-])CN1C(C)=C(CC2=NC3=CC=CC=C3C=C2)C4=C1C=CC(F)=C4.[Na+]


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.90.01


References

1: Bielory L, Schoenberg D. Ocular allergy: update on clinical trials. Curr Opin Allergy Clin Immunol. 2019 Oct;19(5):495-502. doi: 10.1097/ACI.0000000000000564. PubMed PMID: 31465314.

2: Yanes DA, Mosser-Goldfarb JL. Emerging therapies for atopic dermatitis: The prostaglandin/leukotriene pathway. J Am Acad Dermatol. 2018 Mar;78(3 Suppl 1):S71-S75. doi: 10.1016/j.jaad.2017.12.021. Epub 2017 Dec 15. Review. PubMed PMID: 29248523.

3: Kupczyk M, Kuna P. Targeting the PGD(2)/CRTH2/DP1 Signaling Pathway in Asthma and Allergic Disease: Current Status and Future Perspectives. Drugs. 2017 Aug;77(12):1281-1294. doi: 10.1007/s40265-017-0777-2. Review. PubMed PMID: 28612233; PubMed Central PMCID: PMC5529497.

4: Otani IM, Nadeau KC. Biologic Therapies for Immunoglobulin E-mediated Food Allergy and Eosinophilic Esophagitis. Immunol Allergy Clin North Am. 2017 May;37(2):369-396. doi: 10.1016/j.iac.2017.01.010. Review. PubMed PMID: 28366483.

5: Santini G, Mores N, Malerba M, Mondino C, Macis G, Montuschi P. Investigational prostaglandin D2 receptor antagonists for airway inflammation. Expert Opin Investig Drugs. 2016 Jun;25(6):639-52. doi: 10.1080/13543784.2016.1175434. Epub 2016 Apr 25. Review. PubMed PMID: 27094922.

6: McIvor RA. Emerging therapeutic options for the treatment of patients with symptomatic asthma. Ann Allergy Asthma Immunol. 2015 Oct;115(4):265-271.e5. doi: 10.1016/j.anai.2015.07.011. Epub 2015 Aug 5. Review. PubMed PMID: 26254973.

7: Pettipher R, Hunter MG, Perkins CM, Collins LP, Lewis T, Baillet M, Steiner J, Bell J, Payton MA. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459. Allergy. 2014 Sep;69(9):1223-32. doi: 10.1111/all.12451. Epub 2014 Jul 14. PubMed PMID: 24866478.

8: Straumann A, Hoesli S, Bussmann Ch, Stuck M, Perkins M, Collins LP, Payton M, Pettipher R, Hunter M, Steiner J, Simon HU. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy. 2013 Mar;68(3):375-85. doi: 10.1111/all.12096. Epub 2013 Feb 5. PubMed PMID: 23379537.

9: Horak F, Zieglmayer P, Zieglmayer R, Lemell P, Collins LP, Hunter MG, Steiner J, Lewis T, Payton MA, Perkins CM, Pettipher R. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. Allergy. 2012 Dec;67(12):1572-9. doi: 10.1111/all.12042. Epub 2012 Oct 1. PubMed PMID: 23025511.

10: Singh D, Cadden P, Hunter M, Pearce Collins L, Perkins M, Pettipher R, Townsend E, Vinall S, O'Connor B. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. Eur Respir J. 2013 Jan;41(1):46-52. doi: 10.1183/09031936.00092111. Epub 2012 Apr 10. PubMed PMID: 22496329.

11: Pettipher R, Vinall SL, Xue L, Speight G, Townsend ER, Gazi L, Whelan CJ, Armer RE, Payton MA, Hunter MG. Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils. J Pharmacol Exp Ther. 2012 Feb;340(2):473-82. doi: 10.1124/jpet.111.187203. Epub 2011 Nov 21. PubMed PMID: 22106101.

12: Barnes N, Pavord I, Chuchalin A, Bell J, Hunter M, Lewis T, Parker D, Payton M, Collins LP, Pettipher R, Steiner J, Perkins CM. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy. 2012 Jan;42(1):38-48. doi: 10.1111/j.1365-2222.2011.03813.x. Epub 2011 Jul 15. PubMed PMID: 21762224.